AEGiS-PRn: FDA Grants Fast Track Designation for 1.0% C31G Vaginal Gel for the Reduction of HIV Transmission

Important note: Information in this article was accurate in 2003. The state of the art may have changed since the publication date.

FDA Grants Fast Track Designation for 1.0% C31G Vaginal Gel for the Reduction of HIV Transmission

PRNewswire - November 17, 2003

HUNTINGDON VALLEY, Pa., Nov. 17 /PRNewswire/ -- Biosyn, Inc. announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for the development program of 1.0% C31G vaginal gel for the reduction of HIV transmission. In granting the Fast Track designation, the FDA recognized that HIV infection is a serious and life-threatening condition, there is an unmet need for a female controlled method to reduce the sexual transmission of HIV and 1.0% C31G has the potential to address this unmet medical need.

"We have worked closely with the FDA on the clinical path for this candidate since it is an important product for the prevention of sexual transmission of HIV," said Anne-Marie Corner, President & CEO of Biosyn. "The fast track designation will help accelerate our development of C31G vaginal gel."

Fast track programs are designed to facilitate the development and expedite the review of new drug candidates that are intended to prevent or treat serious or life-threatening conditions and that demonstrate the potential to address unmet medical needs.

Biosyn's lead product candidate, 1.0% C31G vaginal gel is entering Phase III clinical trials. Planned studies include prevention of transmission of HIV, prevention of transmission of chlamydia and contraception. Other products in clinical development at Biosyn include UC-781, a non-nucleoside reverse transcriptase inhibitor in Phase I trials for the prevention of HIV transmission, 0.5% C31G oral rinse, a Phase II product candidate for management of oral infections associated with immune-suppression and cyanovirin-N (CV-N), a novel fusion inhibitor in preclinical development for the prevention of transmission of HIV.

About C31G Vaginal Gel

1.0% C31G vaginal gel is in development for contraception and prevention of sexually transmitted diseases (STDs) including HIV, chlamydia and herpes. The United States has the highest rates of STDs in the industrialized world, and of the 40 million women in the United States who are currently using contraception, more than three-quarters are using a method that places them at risk of contracting an STD.

About Biosyn, Inc.

Biosyn is a specialty pharmaceutical company focused on the development and commercialization of novel drugs in the areas of infectious disease and reproductive health. Biosyn's product portfolio offers significant competitive advantages in areas where there is a critical need for new or alternative therapies.

SOURCE Biosyn, Inc.

Web Site: http://www.biosyn-inc.com

031117
PR031131

Copyright © 2003 - PRNewswire. All rights reserved. Reproduced with permission. Reproduction of this article (other than one copy for personal reference) must be cleared through PRNewswire, Permissions, 810 Seventh Ave., 32nd Floor, New York, NY 10019 http://www.prnewswire.com.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Broadway Cares/Equity Fights AIDS, Elton John AIDS Foundation, the National Library of Medicine, Pacific Life Foundation and donations from users like you.

Always watch for outdated information. This article first appeared in 2003. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 2003. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .